MX2021000290A - Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. - Google Patents
Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4.Info
- Publication number
- MX2021000290A MX2021000290A MX2021000290A MX2021000290A MX2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A
- Authority
- MX
- Mexico
- Prior art keywords
- ccr4
- binding domain
- engineered
- compositions
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696746P | 2018-07-11 | 2018-07-11 | |
| PCT/US2019/041324 WO2020014429A2 (en) | 2018-07-11 | 2019-07-11 | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000290A true MX2021000290A (es) | 2021-09-08 |
Family
ID=69142497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000290A MX2021000290A (es) | 2018-07-11 | 2019-07-11 | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250346676A1 (https=) |
| EP (1) | EP3820517A4 (https=) |
| JP (1) | JP2021531756A (https=) |
| KR (1) | KR20210042324A (https=) |
| CN (1) | CN113164590A (https=) |
| AU (1) | AU2019302662A1 (https=) |
| BR (1) | BR112021000391A2 (https=) |
| CA (1) | CA3105985A1 (https=) |
| IL (1) | IL279987A (https=) |
| MX (1) | MX2021000290A (https=) |
| WO (1) | WO2020014429A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4463485A4 (en) * | 2022-01-12 | 2026-02-25 | Biomolecular Holdings Llc | Tetrahedral antibodies |
| US20250084169A1 (en) | 2022-01-12 | 2025-03-13 | Biomolecular Holdings Llc | Nk/monocyte engagers |
| WO2024221187A1 (en) * | 2023-04-24 | 2024-10-31 | Biomap Intelligence Technology Sg Pte.Ltd. | Heteromultimer polypeptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| CA2766065C (en) * | 2009-06-30 | 2020-07-21 | Research Development Foundation | Immunoglobulin fc polypeptides |
| AU2013256010B2 (en) * | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| WO2017151971A2 (en) * | 2016-03-02 | 2017-09-08 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
| BR112018074056A2 (pt) * | 2016-05-23 | 2019-03-06 | Momenta Pharmaceuticals, Inc. | composições e métodos relacionados a construtos de fc manipulados |
-
2019
- 2019-07-11 BR BR112021000391-6A patent/BR112021000391A2/pt not_active IP Right Cessation
- 2019-07-11 AU AU2019302662A patent/AU2019302662A1/en not_active Abandoned
- 2019-07-11 KR KR1020217004244A patent/KR20210042324A/ko not_active Ceased
- 2019-07-11 CA CA3105985A patent/CA3105985A1/en active Pending
- 2019-07-11 EP EP19833821.2A patent/EP3820517A4/en not_active Withdrawn
- 2019-07-11 CN CN201980059453.2A patent/CN113164590A/zh active Pending
- 2019-07-11 MX MX2021000290A patent/MX2021000290A/es unknown
- 2019-07-11 WO PCT/US2019/041324 patent/WO2020014429A2/en not_active Ceased
- 2019-07-11 JP JP2021500823A patent/JP2021531756A/ja not_active Withdrawn
- 2019-07-11 US US17/259,061 patent/US20250346676A1/en active Pending
-
2021
- 2021-01-06 IL IL279987A patent/IL279987A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021531756A (ja) | 2021-11-25 |
| EP3820517A2 (en) | 2021-05-19 |
| WO2020014429A2 (en) | 2020-01-16 |
| AU2019302662A1 (en) | 2021-02-25 |
| KR20210042324A (ko) | 2021-04-19 |
| US20250346676A1 (en) | 2025-11-13 |
| CA3105985A1 (en) | 2020-01-16 |
| IL279987A (en) | 2021-03-01 |
| CN113164590A (zh) | 2021-07-23 |
| BR112021000391A2 (pt) | 2021-04-06 |
| WO2020014429A3 (en) | 2020-02-13 |
| EP3820517A4 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| MX2021000306A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4. | |
| EP3897623C0 (en) | AMINO ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 | |
| CO2021017893A2 (es) | Degradadores de irak y usos de los mismos | |
| MX2021000307A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. | |
| MX2021000290A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| CL2018003290A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| MX2021007925A (es) | Inhibidores irreversibles de la interaccion menina-mll. | |
| MX2022007607A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2. | |
| EA201991598A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR) | |
| EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
| MX384363B (es) | Nuevos polipéptidos de unión específica y usos de los mismos. | |
| AR078516A1 (es) | Moleculas de union a dll-4 (ligando 4 de tipo delta) | |
| MX2020008107A (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. | |
| EA201991600A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR) | |
| MX2019007892A (es) | Compuestos inhibidores de metaloenzimas. | |
| MX420249B (es) | Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos. | |
| MX2021000281A (es) | Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1. | |
| BR112018071592A2 (pt) | inibidores de erbb e usos dos mesmos | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| BR112019003915A2 (pt) | composição para tratamento dos cabelos, método de tratamento de cabelo danificado quimicamente e usos de uma composição | |
| MX2019012506A (es) | Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina. | |
| EA202191403A1 (ru) | Композиция с высокой концентрацией белка | |
| AR119558A1 (es) | Estructuras tipo pirenoide |